Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Ather... ( CARLSBAD Calif. April 18 /- IsisP...)

Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis

Date:4/18/2008

CARLSBAD, Calif., April 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) presented the results of two studies designed to assess the impact of lowering apoB-100 on atherosclerosis at the 2008 Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Conference in Atlanta, Georgia. The data were presented in a poster entitled "Antisense Inhibition of Apolipoprotein B Ameliorated Diet-Induced Hypercholesterolemia and Reduced Atherosclerosis in LDL Receptor-Deficient Mice" by Adam E. Mullick, Ph.D. of Isis yesterday at ATVB.

Both studies were performed in a murine model in which the LDL receptor, which is responsible for the maintenance of normal serum cholesterol levels, has been genetically eliminated. These animals have very high cholesterol levels (1,000 - 2,000 mg/dL on a high fat diet) and develop severe atherosclerosis. In the first study, the impact of treatment with an antisense drug was evaluated in the context of two atherogenic high fat diets. Animals on these diets had elevated total cholesterol and LDL-cholesterol levels that increased during the two weeks of high fat diet prior to drug treatment. These cholesterol levels dramatically decreased during the 10 week treatment period. At a dose of 50 mg/kg twice weekly, the murine apoB-100 antisense drug reduced total cholesterol and LDL-cholesterol by 87% and 93%, respectively. These reductions in cholesterol directly correlated with reduction in liver and plasma apoB-100 levels. Aortic atherosclerotic lesions were reduced by 78% - 92% in the same animals.

The second study, which evaluated the effects of increasing doses of drug on lipid levels, confirms and extends the results of the previous study, and showed that the effects of the apoB-
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
2. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
6. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
7. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
8. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
11. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women

Post Your Comments:

Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Ather...( CARLSBAD Calif. April 18 /- IsisP...),Health